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cense. httpAbstract Background and Aim: Androgen plays a fundamental role in the growth and differenti-
ation of prostate. Androgen receptor (AR) expression may represent a potential marker of progno-
sis in prostate cancer. However, there have been variable results regarding its ability to predict
clinical progression. Despite the oncogenic properties of DJ-1, its signiﬁcance in prostate cancer
development and progression is not well understood. This research shed some light on the possible
role of immunohistochemical expression of DJ-1 in clinically localized prostatic carcinoma in rela-
tion to the established role of AR and other clinicopathologic parameters.
Materials and Methods: The immunohistochemical expression of AR and DJ-1 was evaluated in
129 samples including benign hyperplasia (n= 60) and prostatic carcinoma (n= 69).
Results: The mean value of AR immunostaining was signiﬁcantly higher in prostatic carcinomas
than in benign hyperplasia (P= 0.001). A signiﬁcant inverse correlation was found between AR
immunostaining and the grade of prostatic carcinomas. A signiﬁcantly higher median DJ-1 score
was found in prostatic carcinoma than in benign hyperplasia (P= 0.0001). There was a signiﬁcantH, benign prostatic hyperpla-
state speciﬁc antigen; DHT,
al resection of the prostate
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Table 1 Comparison between pros
Grade
Low grade (n= 24)
Moderate grade (n= 18)
High grade (n= 27)
Lymph node status
Negative
Positive
* Kruskal wallis.
** Mann Whitney test.
224 W.M. Osman et al.direct correlation between AR and DJ-1 score (P= 0.0001). AR is more sensitive in predicting
prostatic carcinoma than DJ-1 but DJ-1 is more speciﬁc than AR.
Conclusion: AR nuclear expression was consistently present in benign and adenocarcinoma epithe-
lium. But, there may be limited clinical use for AR expression in localized carcinoma due to its con-
stant heterogeneity. DJ-1 with its oncogenic properties, speciﬁcity for prostatic carcinoma and
homogenous expression gives an ideal complementary role to AR in the detection and treatment
of prostatic carcinomas.
ª 2013 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.
Open access under CC BY-NC-ND license.Introduction
Prostate cancer (PCa) is the most frequently diagnosed malig-
nancy and the second leading cause of death as a result of can-
cer in men in industrial countries. Notwithstanding the
importance of this malignancy, little is understood about its
cause. Androgens, mainly testosterone and 5-alphadihydrotes-
tosterone (DHT), play a fundamental role in the growth, dif-
ferentiation and maintenance of prostate tissue. Their effects
are mediated via a speciﬁc androgen receptor (AR) that be-
longs to the nuclear receptor family [1].
The AR molecule is a major part of the regulatory Andro-
gen-AR complex and is therefore critical in the androgen-AR
pathway of PCa [2,3]. AR expression may represent a potential
marker of prognosis and hormonal responsiveness in PCa.
However, there have been variable results regarding the num-
ber of cells expressing ARs in cancer and the ability to predict
clinical progression [1,4–16].
Laboratories throughout the world strive to understand how
AR is controlled in all stages of prostate development and can-
cer progression. There is a subset of anti-androgen-regulated
genes that may allow the androgen receptor to escape anti-
androgen therapy and promote disease progression. This is a
compelling idea – perhaps the treatment itself drives disease pro-
gression [17]. This research speciﬁcally addresses this hypothesis
by focusing on the DJ-1 oncogene in prostate cancers.
Human DJ-1 is located at 1p36.33-1p36.12 and is composed
of 7 exons encoding a 20 kilo-Dalton protein. DJ-1 is a ubiq-
uitous cytoplasmic and nuclear oncogene also known as
PARK7 [18,19]. DJ-1 was initially identiﬁed by Nagakubo
and colleagues [20] who determined that increased DJ-1
expression possesses an oncogenic property. Since this initial
discovery and characterization, DJ-1 has been associated with
multiple signaling pathways and human diseases [18,19,21–26].
In addition to Parkinson’s disease, DJ-1 has been impli-
cated in adenocarcinomas of the lung, breast, and prostatetatic carcinoma grades and lymp
HSCORE
Median IQR
2.1 1.5–3.0
1.0 0.8–1.5
1.5 0.8–2.3
2.00 1.00–2.4
1.50 0.75–2.0[22–26]. Despite the oncogenic properties of DJ-1, its func-
tional signiﬁcance in prostate cancer development and progres-
sion is not well understood. The importance of PTEN in PCa
is well documented [27] and although it is likely that DJ-1
antagonizes PTEN in prostate cancer as in breast cancer, this
interaction has not yet been deﬁned in prostate [17].
Consequently, this research, for the ﬁrst time, shed some
light on the possible role of immunohistochemical expression
of DJ-1 in clinically localized prostatic carcinoma in relation
to the well established role of AR and other clinicopathologic
parameters including Gleason score.
Materials and methods
A retrospective study included 129 prostatectomy specimens
[69 prostatic adenocarcinoma cases (without capsular invasion)
and 60 benign prostatic hyperplasia (BPH) cases] that were sur-
gically resected in the time period from January 2010 to Janu-
ary 2012. The specimens were retrieved from the archival ﬁles
of the pathology labs of Ain Shams University Hospitals.
The specimens of clinically localized prostatic adenocarcinoma
were collected after excluding specimens that belonged to pa-
tients with a past history of preoperative neo-adjuvant hor-
monal therapy or chemotherapy. The BPH specimens were
collected after excluding those associated with either prostate
speciﬁc antigen (PSA) level >20, prostatitis, abscess, infarction
or those diagnosed through trans urethral resection of the pros-
tate (TURP) (these may inﬂuence serum PSA levels and hence
interfere with the results’ validity). The clinical data concerning
the patients’ age and PSA value were obtained from the pa-
tients’ medical records. Revision of the hematoxylin and eosin
stained slides was carried out to conﬁrm the Gleason score, the
lymph node status, and the presence of sufﬁcient suitable mate-
rial for immunohistochemical staining.
Immunohistochemical staining: Four micrometer sections of
formalin – ﬁxed and parafﬁn – embedded samples of all casesh node status as regards HSCORE.
Test P Sig
19.6* 0.0001 HS
8 1.816** 0.069 NS
0
Figure 1 (a) Moderate and focal AR nuclear staining in benign
prostatic hyperplasia (AR · 200). (b) Strong AR nuclear staining
in low grade prostatic carcinoma (AR · 200). (c) Negative AR
nuclear staining in high grade prostatic carcinoma (AR · 200).
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using primary antibodies; AR antibody Ab-1 (mouse monoclo-
nal antibody, ready to use Cat. No; MS-443-R7, Thermo Sci-
entiﬁc, CA, USA) and DJ-1 antibody (mouse monoclonalantibody, dil (1:20), Cat # 37–8800, Cell marque, CA, USA).
The Avidin–Biotin immunoperoxidase complex technique
was used by applying the super sensitive detection kit (Bioge-
nex, CA, USA). The prepared tissue sections were ﬁxed on
poly-L-lysine coated slides overnight at 37 C. They were depa-
rafﬁnized and rehydrated through graded alcohol series. Then,
sections were bathed in a 103 m sodium citrate buffer (pH
6.0) after bringing the solution to a boil in a pressure cooker
and boiled for 20 min while maintaining the pressure. After
quenching in 3% hydrogen peroxide and blocking for 5 min,
the sections were incubated overnight at 4 C with primary
antibody. Biotinylated antimouse immunoglobulin and strep-
tavidin conjugated to horseradish peroxidase were then added.
Finally, 3,30-diaminobenzidine as the substrate or chromogen
was used to form an insoluble brown product. Hematoxylin
was used as counter stain for AR and DJ-1. Mounting in Can-
ada balsam was followed. Positive control for DJ-1 was pros-
tatic and kidney tissue, while positive control for AR was
prostatic carcinoma. Negative controls had primary antibody
replaced by buffer.
Interpretation of AR immunostaining
The results of immnohistochemical staining were assessed by
all authors and a consensus regarding controversial cases
was reached at a multiheaded microscope.
Owing to the AR-heterogeneous content of positive stain-
ing cells in the specimens, each of the slides was scanned to ﬁnd
the areas of highest staining and the histological score
(HSCORE) was used, which is a measure of both the intensity
and distribution of staining. The HSCORE was calculated
using the equation: HSCORE= RPi (i + 1). The intensity of
staining (i) was evaluated subjectively on a scale of 0–3, where
0 = no staining, 1 = weak equivocal staining, 2 = unequivo-
cal moderate staining and 3 = strong staining. Pi is the per-
centage of stained epithelial cells having the same intensity.
This semi-quantitative analysis has been shown to have a
low intra-observer and inter-observer error. The areas of focal
staining with the highest percentage of nuclei for AR were used
in each Gleason pattern observed in a particular tumor. If
more areas from the same pathological category were identi-
ﬁed within one prostate, the highest score was taken for that
category [1].
Interpretation of DJ-1 immunostaining
DJ-1 immunohistochemical staining was done and quantitated
based on intensity. Four areas per tissue were evaluated using
the following scale: 0, no staining of any cells; 1, faint staining;
2, moderate intensity staining; and 3, intense staining [17].
Statistical analysis
Mann Whitney test was used to compare numerical variables
between the two study groups for non-parametric distribution
of data. Kruskal Wallis test was used to compare numerical
variable between more than two study groups for non- para-
metric distribution of data. For pairwise comparison Mann
Whitney test with Bonferroni adjustment was used. Spear-
man’s correlation was used to assess the correlation between
variables. The ROC Curve (receiver operating characteristic)
Table 2 Comparison between prostatic carcinoma grades and lymph node status as regards DJ-1.
DJ-1 score Test P value Sig
Median IQR
Grade
Low grade (n= 24) 2 1.5–2.5 5.2* 0.74 NS
Moderate grade (n= 18) 1 0–2
High grade (n= 27) 2 1–3
Lymph node status
Negative 2 1–3 1.309** 0.19 NS
Positive 1 1–2
* Kruskal Wallis.
** Mann-Whitney.
226 W.M. Osman et al.was used to evaluate the sensitivity and speciﬁcity of DJ-1 and
HSCORE in prediction of cancer among cases. McNemar’s
test was used for the comparison between the sensitivities
and speciﬁcities of both markers.
A signiﬁcance level of P < 0.05 was used in all tests. All
statistical procedures were carried out using SPSS version 15
for Windows (SPSS Inc., Chicago, IL, USA).
Results
Clinicopathologic results
In prostatic carcinoma patients, the mean age was 66.4 ± 5.5,
range (56–80) and the mean PSA value was 37.5 ± 12.2, range
(18–75). Lymph node metastasis was detected in 21 out of 69
cases (30.4%). The prostatic carcinoma cases were histologi-
cally classiﬁed into 24 cases of low grade carcinomas (Gleason
score 6), 18 cases of moderate grade carcinomas (Gleason
score7) and 27 cases of high grade carcinomas (Gleason score
8 and 9).
Immunohistochemical results
Regarding AR immunostaining
AR immunoreactivity was almost exclusively nuclear and was
observed in the tumor cells, non-neoplastic glandular epithelial
cells. AR-positive cells were heterogeneously distributed. In
this study, intense staining was intermingled with areas that
lacked staining. There was a high signiﬁcant difference be-
tween the median of AR immunostaining in prostatic carcino-
mas (2.00, IQR= 1.00–2.00) and the median of AR
immunostaining in BPH cases (.00, IQR= .00–1.00), (Mann
Whitney test = 7.194, P= 0.0001) (Data not tabulated).
Although a signiﬁcant inverse correlation was found be-
tween AR immunostaining and the grade of prostatic carcino-
mas, the strength of correlation was weak (rho = 0.336,
P= 0.005). On further comparison between each 2 grades,
the Mann Whitney test with Bonferroni adjustment, revealed
a signiﬁcant difference in the median HSCORE between low
and moderate grade carcinomas and between low and high
grade carcinomas (P= 0.001). A comparison of AR expres-
sion in the grade and lymph node status of prostatic carcino-
mas is presented in Table 1.
AR expression did not correlate with other clinicopatho-
logic features such as age (rho = 0.041, P= 0.738) and
pre-treatment PSA (rho = 0.129, P= 0.292). Fig. 1 showsrepresentative areas for AR expression in BPH and prostatic
carcinoma.
Regarding DJ-1 immunostaining
Cytoplasmic DJ-1 was expressed in luminal epithelial cells and
was relatively weak; or even negative, in non-neoplastic pros-
tatic epithelium specimens. A signiﬁcant difference in the med-
ian DJ-1 score was found between prostatic carcinomas (1.5,
IQR= 1–2.25) and BPH cases (0.5, IQR= 0.5–0.75) (Mann
Whitney = 6.733, P= 0.0001) (Data not tabulated).
DJ-1 was expressed in different grades of prostatic carci-
noma, with no statistically signiﬁcant differences between
them, indicating loss of a signiﬁcant correlation between grade
and DJ-1 score (rho = 0.076, P= 0.537). Table 2 shows the
statistical results concerning the relation between DJ-1 score
and the grade of prostatic carcinomas. Moreover, there was
no signiﬁcant difference between the DJ-1 median score in
lymph node positive carcinomas and the DJ-1 median score
in lymph node negative carcinomas (Table 2).
DJ-1expression did not correlate with other clinicopatho-
logic features such as age (rho = 0.107, P= 0.381), and
pre-treatment PSA (rho = 0.072, P= 0.559).
Fig. 2 shows representative areas for DJ-1 expression in
BPH and prostatic carcinoma.
Relationship between both markers
There was a high signiﬁcant direct correlation between AR
(HSCORE) and DJ-1 score (rho = 0.767, P= 0.0001)
(Fig. 3). AR was more sensitive (79.9%) than DJ-1 (58%) in
predicting prostatic carcinoma (P= 0.001), while DJ-1 was
more speciﬁc (98.3%) in this respect (P= 0.003). (Table 3)
(Figs. 4 and 5).
Discussion
In the normal prostate, there is a balance between the number
of cells proliferating and cells undergoing apoptosis resulting
in maintenance of the size of the gland. AR is one of the most
important genes that has been implicated in PCa development
and progression. Androgens regulate the proliferation rates of
epithelial cells, the predominant cell type involved in adenocar-
cinoma, so increased androgen levels or AR activity could re-
sult in uncontrolled proliferation and cancer development. AR
is required for normal prostate function and is expressed in
PIN and early carcinoma; however it is also expressed in ad-
vanced and metastatic carcinoma [27–30]. Similar to previous
Figure 2 (a) Weak DJ-1 expression in benign prostatic hyper-
plasia (DJ-1 · 100). (b) Strong DJ-1 immunostaining in low grade
prostatic carcinoma (DJ-1 · 200). (c) Strong DJ-1 immunostaining
in high grade prostatic carcinoma (DJ-1 · 200).
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Figure 3 Direct correlation between HSCORE and DJ-1.
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specimens passing from the benign hyperplastic epithelium up
to the different grades of prostatic carcinoma.Qiu et al. [1] stated there have been variable results regard-
ing the number of cells expressing AR and recommended the
use of HSCORE. For proper evaluation and comparison; same
method for assessment was used in the current research. Het-
erogeneity of AR expression within individual tumor foci sug-
gests that AR expression may not be required for the survival
of each individual prostate cancer cell. It is possible that AR
positive cells are necessary within a prostate tumor mass to
sustain local growth factor conditions [29–31].
AR immune-positivity was signiﬁcantly lower in benign
glands than in the secretory malignant epithelium within the
same sections, which is consistent with previous reports of
Qiu et al. [1], Gaston et al. [15] and Heinlein and Chang
[29]. This reﬂects the importance of AR expression in the early
stages of PCa carcinogenesis.
In our study, there was a signiﬁcant inverse correlation be-
tween AR expression in PCa and the tumor grade. A greater
AR content in patients with a low Gleason score compared
with those with a high Gleason score, as proved by our study,
has also been previously reported [4,5,6,29]. This ﬁnding to-
gether with the signiﬁcant difference in AR (HSCORE) ob-
served in our study between low grade carcinomas and each
of the moderate and high grade carcinomas provides further
evidence for the importance of AR in prostatic cancer carcino-
genesis rather than its progression. However; other studies
achieved different results as regards the relation between AR
expression and the grade of PCa [8,9,11,13]. The heterogeneity
of AR immunostaining and multi-focality of PCa sustained to
be very important factors that resulted in different observa-
tions in the literature.
In the present study we found a sub group of AR- negative
PCa having positive LN metastasis, a new supporting evidence
for the study of Pertschuk et al. [10] who found that certain
men with AR-negative PCa had a worse prognosis than those
with AR-positive PCa but failed to ﬁnd any correlation be-
tween AR density with grade, stage or ethnicity. This may be
explained by the fact that in untreated prostate cancer, the
presence of AR mutations is generally found to increase with
cancer stage. Mutations in the AR gene have been detected
in about 10–20% of prostate cancer specimens. The frequency
of mutation generally appears higher in hormone-refractory,
Figure 4 ROC curve for sensitivity and speciﬁcity of HSCORE
in prediction of prostatic carcinoma.
Figure 5 ROC curve for sensitivity and speciﬁcity of DJ-1 in
prediction of prostatic carcinoma.
Table 3 Sensitivity and speciﬁcity of each of HSCORE and DJ-1 in predicting prostatic carcinoma.
AUC 95% CI Sensitivity
(%)
Speciﬁcity
(%)
PPV
(%)
NPV
(%)
LR+ LR Diagnostic
accuracy (%)
P Sig.
HSCORE Malig if > 0.87 0.861 0.796–0.925 79.9 80 82 77.4 3.986 0.254 79.8 0.0001 HS
DJ-1 score Malig if > 1.5 0.827 0.756–0.899 58 98.3 97.5 67 34.783 0.427 76.7 0.0001 HS
228 W.M. Osman et al.metastatic tumors compared with untreated lower-grade pri-
mary tumors [32–36]. Others found that AR mutations are ob-
served in 21–44% of metastatic tumors sampled before therapy
[16,36].
In the present study, AR expression did not correlate with
the other clinicopathological features, such as age and preop-
erative PSA level. Same conclusions were previously reported
[13–15,37].
Studies have shown that the occurrence and development of
malignant tumors are closely related to the over expression of
some oncogenes and apoptosis inhibitory factors. AR regu-
lates a number of other genes through numerous interactions
with co-activators and co-repressors. As a mitogen dependent
oncogene, DJ-1 has become a research focus in the last years
[17,37,38]; and is selectively used in our research to compare
its expression with that of AR receptors.
Therefore, this project is one of the ﬁrst-steps in the on-
going process of sorting out the multiple functions of human
DJ-1 in prostate. DJ-1 is predominantly expressed in luminal
epithelial cells and is mainly cytoplasmic. DJ-1 is a diverse sig-
naling protein that seems to have multiple roles that may lar-
gely depend on cell type and cellular environment [18,20–
22,24–26]. In prostate cancer, the subcellular localization of
DJ-1 is regulated by androgens and anti-androgens [17].
In this study, we found that cytoplasmic DJ-1expression
was signiﬁcantly weak in non-neoplastic prostatic epithelium
specimens compared with their prostatic carcinoma counter-parts, suggesting that an increase in cytoplasmic DJ-1 might
be important in the neoplastic transformation in prostate. This
ﬁnding corresponded to the literature data which suggested
that DJ-1 protein is a perspective biomarker candidate for
PCa, due to its differential expression between PCa and BPH
patients [39]. DJ-1 functions to promote carcinogenesis
through inhibition of PTEN, a potent tumor suppressor, which
inhibits the survival pathway, PI3K pathway [22].
Additionally, the importance of this study was emphasized
in evaluating DJ-1 staining intensity in relation to Gleason
score. In this study, DJ-1 expression was higher in low and
high grade prostatic carcinomas compared to moderate grade
carcinomas but the difference did not reach a signiﬁcant level.
Similar results were documented by Tillman et al. [17] who de-
clared that DJ-1 does not increase with the Gleason pattern
and no statistically signiﬁcant change was observed between
different Gleason patterns. In addition, there was no signiﬁ-
cant difference between DJ-1 expression in groups with and
without lymph node metastasis. Same conclusions were previ-
ously reported regarding DJ-1 expression in many other or-
gans [37,38]. Therefore, the current study did not ﬁnd the
evidence for the role of DJ-1 in PCa lymph node metastasis.
In the present study, DJ-1 expression did not correlate with
the other clinicopathological features, such as age and preop-
erative PSA level.
Oncogenesis is a complex process involving multiple onco-
genes and signal pathways; the combination use of oncogenes
DJ-1 and androgen receptor immunohistochemical expression in prostatic carcinoma 229as cancer markers may be more convincing than the use of a
single molecular marker [37]. There are several conﬂicting re-
ports regarding the relationship between DJ-1 and AR
[17,25]. In the present study, we found that there is a signiﬁcant
direct correlation between DJ-1 and AR expressions. This ﬁnd-
ing supports Tillman et al. [17] and Pitkanen-Arsiola et al. [40]
who reported that DJ-1 could be an androgen receptor co acti-
vator, which interacts with androgen receptor, and is up-regu-
lated in human prostate cancer on androgen deprivation
therapy. Therefore DJ-1 protein levels could increase in paral-
lel with AR in response to antiandrogen therapy indicating
that DJ-1 may contribute to the development of androgen
independent PCa.
In primary lung cancer patients, the recurrence rate of pa-
tients with high-level of DJ-1 was detected [41]. In cervical tis-
sues, DJ-1 was obviously increased and might be used as a
cervical cancer progression marker [42]. A positive relationship
of DJ-1 with tumor invasion and metastasis was found in
hepatocellular carcinoma [43], and DJ-1 was also highlighting
an important role in chemoresistance [44]. Also, a potential use
of serum DJ-1 as a tumor marker has been suggested in some
cancers [42,44,45].
In conclusion, AR nuclear expression was consistently pres-
ent in benign and adenocarcinoma epithelia. Inspite of the high
AR sensitivity in PCa in relation to DJ-1, its constant hetero-
geneity may hinder its expanded use in the clinical ﬁeld. There-
fore, this research shed some light on the potential important
role of DJ-1 in PCa and provided preliminary data for future
DJ-1 research in PCa. This study proved the carcinogenic
property of DJ-1 in PCa due to its differential expression in be-
nign prostatic hyperplasia and adenocarcinomas. The direct
correlation between DJ-1 and AR, moreover, the relative high
DJ-1 speciﬁcity, its homogenous immune-expression were
other outcomes achieved in this study.
Eventually, the present study deduced that DJ-1 could be
an attractive target to be studied as an immunohistochemical
marker for prostate cancer.
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